Adult cerebellar anaplastic astrocytomas (cAA) are rare entities and their clinical and genetic appearances are still ill defined. Previously, malignant gliomas of the cerebellum were combined and reviewed together (cAA and cerebellar glioblastomas (cGB), that could have possibly affected overall survival (OS) and progression-free survival (PFS). We present characteristics of 15 adult patients with cAA and compared them to a series of 45 patients with a supratentorial AA (sAA) in order to elicit the effect of tumor location on OS and PFS. The mean age at cAA diagnosis was 39.3 years (range 19-72). A history of neurofibromatosis type I was noted in 1 patient (6.7%). An IDH-1 mutation was identified in 6/15 cases and a methylated MGMT promoter in 5/15 cases. Patients in study and control groups were matched in age, sex and IDH-1 mutation status. Patients in a study group tended to present with longer overall survival (50 vs. 36.5 months), but the difference did not reach statistical significance. In both cAA and supratentorial AA groups presence of the IDH-1 mutation remains a positive predictor for the prolonged survival. The present study suggests that adult cAA constitute a group of gliomas with relatively higher rate of IDH-1 mutations and prognosis similar to supratentorial AA. The present study is the first to systematically compare cAA and supratentorial AA with respect to their genetic characteristics and suggests that both groups show a similar survival prognosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jocn.2021.07.010 | DOI Listing |
Med Phys
December 2024
Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Background: Quantitative blood oxygenation level-dependent (qBOLD) technique can be applied to detect tissue damage and changes in hemodynamic in gliomas. It is not known whether qBOLD-based radiomics approaches can improve the prediction of isocitrate dehydrogenase-1 (IDH-1) mutation.
Purpose: To establish a qBOLD-based clinical radiomics-integrated model for predicting IDH-1 mutation in gliomas.
Front Oncol
November 2024
Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, China.
Introduction: The CD16A protein encoding gene FcγRIIIa () and its potential ligand Fibrinogen-like protein 2 () are involved in various cell physiological activities on the extracellular surface. Aberrant expression of these genes has been linked to tumorigenesis.
Methods: To assess the prognostic significance of and transcription expression in glioma and explore their roles in glioma initiation and progression, we utilized multiple online databases, including TCGA, GEPIA, CGGA, cBioPortal, TISCH, LinkedOmics, Ivy Glioblastoma Atlas Project, and Human Protein Atlas.
Mol Clin Oncol
January 2025
Department of Radiology, Tangshan Gongren Hospital, Tangshan, Hebei 063000, P.R. China.
O6-methylguanine DNA methyltransferase () promoter methylation is associated with the prognosis of patients with glioblastomas. With the aim of facilitating the discrimination of glioblastoma molecular phenotypes and improving the accuracy of molecular imaging diagnosis, the present retrospective study analyzed the association between promoter methylation and glioblastoma magnetic resonance imaging (MRI) texture features and prognosis. A total of 128 patients with pathologically diagnosed glioblastoma who had undergone preoperative MRI were enrolled.
View Article and Find Full Text PDFAnn Afr Med
November 2024
Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
J Neurooncol
October 2024
Department of Neurosurgery, University of Colorado School of Medicine, Anschutz Medical Campus, 12605 E. 16th Ave, Aurora, CO, 80045, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!